Summary

Market Overview
The Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market was valued at USD 13.05 Billion in 2024 and is projected to reach USD 18.41 Billion by 2030, growing at a CAGR of 6.10% during the forecast period. Contract Development and Manufacturing Organizations (CDMOs) have become indispensable partners for pharmaceutical and biotechnology companies, offering capabilities in drug formulation, active pharmaceutical ingredient (API) production, and commercial-scale manufacturing. Increasingly, companies are outsourcing these operations to reduce capital investments, improve speed to market, and maintain agility in the face of evolving regulatory frameworks and market conditions. This trend is especially pronounced in the biopharmaceutical sector, where the complexity of producing biologics, biosimilars, and cell and gene therapies necessitates advanced technologies and rigorous quality standards. Although growth prospects are robust, market players must contend with rising regulatory complexity and the need for continuous investment in compliance infrastructure.
Key Market Drivers
Growth in Healthcare Industry
The rapid expansion of the global healthcare sector, generating over USD 4 trillion in annual revenue, is a significant growth driver for the pharmaceutical and biopharmaceutical contract manufacturing market. With pharmaceuticals and biotechnology contributing nearly USD 850 billion and medical technology and diagnostics adding over USD 400 billion, the healthcare industry is witnessing a growing need for efficient drug production and scalable manufacturing capabilities. To meet these demands, drug developers are increasingly outsourcing to CDMOs, allowing them to focus on R&D and commercialization while leveraging external partners' infrastructure and regulatory expertise. The high costs and long development timelines associated with new drug development—ranging between USD 314 million and USD 4.46 billion—further incentivize the use of contract manufacturers to manage costs, accelerate production, and ensure compliance with evolving regulatory standards.
Key Market Challenges
Complexity in Biopharmaceutical Manufacturing
Biopharmaceutical manufacturing presents considerable complexity, making it a critical challenge for contract manufacturing organizations. Unlike conventional small-molecule drugs, biopharmaceuticals—such as monoclonal antibodies, vaccines, and cell and gene therapies—are derived from living organisms, making their production highly sensitive to variables like temperature, pH, and raw material quality. This complexity necessitates precise control of upstream and downstream processes, as even minor deviations can compromise product safety and efficacy. Consequently, CDMOs must make substantial investments in advanced infrastructure, process optimization, and quality management systems. These demands often lead to longer development cycles and increased operational costs, requiring CDMOs to maintain high levels of expertise and resource allocation.
Key Market Trends
Increased Focus on Cell and Gene Therapy Manufacturing
A defining trend in the market is the rising focus on cell and gene therapy manufacturing. With 76 such therapies launched globally by the end of 2023—more than double the number from a decade prior—this segment is gaining traction due to its promise of targeted, curative treatments for complex diseases. Unlike traditional drug manufacturing, cell and gene therapies involve highly specialized, patient-specific processes that require stringent quality control, cutting-edge bioprocessing, and regulatory precision. Due to these challenges, pharmaceutical companies are increasingly partnering with CDMOs that possess proven capabilities in handling advanced therapeutic modalities. These partnerships enable faster development timelines, greater scalability, and improved regulatory compliance, reinforcing the role of CDMOs as strategic allies in the evolving therapeutic landscape.
Key Market Players
• Jubilant Pharmova Limited
• JRS PHARMA GmbH & Co.
• Boehringer Ingelheim GmbH
• Lonza Group
• Rentschler Biotechnologie GmbH
• Inno Biologics Sdn Bhd
• INCOG BioPharma Services
• Baxter Biopharma Solutions
• Catalent Pharma Solutions
• Kemwell Biopharma Private Limited
Report Scope
In this report, the Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
• Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Product Type:
o Active Pharmaceutical Ingredients (API)
o Finished Dosage Formulation
o Advanced Drug Delivery Products
o Over the Counter (OTC) Medicines
o Others
• Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Service:
o Pharmaceutical Manufacturing Services
o Biologics Manufacturing Services
o Drug Development Services
o Others
• Pharmaceutical & Biopharmaceutical Contract Manufacturing Market, By Region:
o North America
§ United States
§ Canada
§ Mexico
o Europe
§ France
§ United Kingdom
§ Italy
§ Germany
§ Spain
o Asia Pacific
§ China
§ India
§ Japan
§ Australia
§ South Korea
o South America
§ Brazil
§ Argentina
§ Colombia
o Middle East & Africa
§ South Africa
§ Saudi Arabia
§ UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market.
Available Customizations
Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
• Detailed analysis and profiling of additional market players (up to five).

ページTOPに戻る

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Impact of COVID-19 on Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market
5. Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Active Pharmaceutical Ingredients (API), Finished Dosage Formulation, Advanced Drug Delivery Products, Over the Counter (OTC) Medicines, Others)
5.2.2. By Service (Pharmaceutical Manufacturing Services, Biologics Manufacturing Services, Drug Development Services, Others)
5.2.3. By Region
5.2.4. By Company (2024)
5.3. Market Map
6. North America Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Service
6.2.3. By Country
6.3. North America: Country Analysis
6.3.1. United States Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product Type
6.3.1.2.2. By Service
6.3.2. Mexico Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product Type
6.3.2.2.2. By Service
6.3.3. Canada Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product Type
6.3.3.2.2. By Service
7. Europe Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Service
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product Type
7.3.1.2.2. By Service
7.3.2. Germany Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product Type
7.3.2.2.2. By Service
7.3.3. United Kingdom Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product Type
7.3.3.2.2. By Service
7.3.4. Italy Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product Type
7.3.4.2.2. By Service
7.3.5. Spain Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product Type
7.3.5.2.2. By Service
8. Asia Pacific Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Service
8.2.3. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product Type
8.3.1.2.2. By Service
8.3.2. India Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product Type
8.3.2.2.2. By Service
8.3.3. South Korea Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product Type
8.3.3.2.2. By Service
8.3.4. Japan Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product Type
8.3.4.2.2. By Service
8.3.5. Australia Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product Type
8.3.5.2.2. By Service
9. South America Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Service
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product Type
9.3.1.2.2. By Service
9.3.2. Argentina Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product Type
9.3.2.2.2. By Service
9.3.3. Colombia Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product Type
9.3.3.2.2. By Service
10. Middle East and Africa Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Service
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product Type
10.3.1.2.2. By Service
10.3.2. Saudi Arabia Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product Type
10.3.2.2.2. By Service
10.3.3. UAE Pharmaceutical & Biopharmaceutical Contract Manufacturing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product Type
10.3.3.2.2. By Service
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Disruptions : Conflicts, Pandemics and Trade Barriers
14. Global Pharmaceutical & Biopharmaceutical Contract Manufacturing Market: SWOT Analysis
15. Porters Five Forces Analysis
15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products
16. Competitive Landscape
16.1. Jubilant Pharmova Limited
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (As Reported)
16.1.5. Recent Developments
16.1.6. Key Personnel Details
16.1.7. SWOT Analysis
16.2. JRS PHARMA GmbH & Co.
16.3. Boehringer Ingelheim GmbH
16.4. Lonza Group
16.5. Rentschler Biotechnologie GmbH
16.6. Inno Biologics Sdn Bhd
16.7. INCOG BioPharma Services
16.8. Baxter Biopharma Solutions
16.9. Catalent Pharma Solutions
16.10. Kemwell Biopharma Private Limited
17. Strategic Recommendations
18. About Us & Disclaimer